Open-label Extension Study of Brazikumab in Crohn’s Disease - INTREPID OLE

Study identifier:D5271C00002

ClinicalTrials.gov identifier:NCT03961815

EudraCT identifier:2019-001866-14

CTIS identifier:N/A

Terminated/Withdrawn

Official Title

An Open-label, Long-term Extension Study of Brazikumab in Participants With Moderately to Severely Active Crohn’s Disease (INTREPID OLE)

Medical condition

Crohn’s disease, IBD

Phase

Phase 3

Healthy volunteers

No

Study drug

Brazikumab Induction Dose, Brazikumab Maintenance Dose

Sex

All

Actual Enrollment

18

Study type

Interventional

Age

18 Years - 80 Years

Date

Study Start Date: 06 Jan 2020
Primary Completion Date: 19 Sept 2023
Study Completion Date: 19 Sept 2023

Study design

Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Sept 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria